Disease Models
- Oncology Models
-
Inflammation & Autoimmune Disease Models
- Rheumatoid Arthritis Models
- Glomerulonephritis Models
- Multiple Sclerosis (MS) Models
- Ocular Inflammation Models
- Sjögren's Syndrome Model
- LPS-induced Acute Lung Injury Model
- Peritonitis Models
- Passive Cutaneous Anaphylaxis Model
- Delayed-Type Hypersensitivity (DTH) Models
- Inflammatory Bowel Disease Models
- Systemic Lupus Erythematosus Animal Models
- Oral Mucositis Model
- Asthma Model
- Sepsis Model
- Psoriasis Model
- Atopic Dermatitis (AD) Model
- Scleroderma Model
- Gouty Arthritis Model
- Carrageenan-Induced Air Pouch Synovitis Model
- Carrageenan-Induced Paw Edema Model
- Experimental Autoimmune Myasthenia Gravis (EAMG) Model
- Graft-versus-host Disease (GvHD) Models
-
Cardiovascular Disease Models
- Surgical Models
- Animal Models of Hypertension
- Venous Thrombosis Model
- Atherosclerosis model
- Cardiac Arrhythmia Model
- Hyperlipoidemia Model
- Doxorubicin-induced Heart Failure Model
- Isoproterenol-induced Heart Failure Model
- Arterial Thrombosis Model
- Pulmonary Arterial Hypertension (PAH) Models
- Heart Failure with Preserved Ejection Fraction (HFpEF) Model
-
Neurological Disease Models
- Alzheimer's Disease Modeling and Assays
- Seizure Models
- Parkinson's Disease Models
- Ischemic Stroke Models
- Acute Spinal Cord Injury (ASCI) Model
- Traumatic Brain Injury (TBI) Model
- Hypoxic-Ischemic Encephalopathy (HIE) Model
- Tourette Syndrome (TS) Model
- Amyotrophic Lateral Sclerosis (ALS) Model
- Huntington's Disease (HD) Model
- Intracerebral hemorrhage (ICH) Models
- Schizophrenia Model
- Pain Models
-
Metabolic Disease Models
- Type 1 Diabetes Mellitus Model
- Type 2 Diabetes Mellitus Model
- Animal Model of Hyperuricemia
-
Nonalcoholic Fatty Liver Disease Model
- High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
- Methionine and Choline Deficient (MCD) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
- Gubra-Amylin NASH (GAN) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
- Streptozotocin (STZ) & High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
- High Fat Diet-Induced Obesity Model
- Diabetic Foot Ulcer (DFU) Model
- Liver Disease Models
- Rare Disease Models
- Respiratory Disease Models
- Digestive Disease Models
-
Urology Disease Models
- Cisplatin-induced Nephrotoxicity Model
- Unilateral Ureteral Obstruction Model
- 5/6 Nephrectomy Model
- Renal Ischemia-Reperfusion Injury (RIRI) Model
- Diabetic Nephropathy (DN) Models
- Passive Heymann Nephritis (PHN) Model
- Adenine-Induced Chronic Kidney Disease (CKD) Model
- Kidney Stone Model
- Doxorubicin-Induced Nephropathy Model
- Orthotopic Kidney Transplantation Model
- Orthopedic Disease Models
- Ocular Disease Models
- Infectious Disease Models
- Skin Disease Models
- Otology Disease Models
Erectile Dysfunction (ED) Models
Creative Bioarray is pleased to introduce our comprehensive Erectile Dysfunction (ED) Models, specifically developed to support researchers in evaluating the efficacy of innovative therapies for ED. Our models provide a reliable platform for advancing scientific understanding and treatment options for this prevalent condition.
What is Erectile Dysfunction (ED)?
ED is a common sexual disorder characterized by the inability to achieve or maintain a satisfactory erection, impacting both the individual and their partner. Its prevalence increases with age and can stem from physiological, psychological, or hormonal disturbances in various systems, including nervous, cardiovascular, and reproductive. ED can be classified as psychogenic, organic (e.g., hormonal or drug-induced), or a combination of both. While PDE5 inhibitors are effective treatments, side effects, cost, and limited efficacy in certain populations highlight the need for better options. Research is focused on developing safer, more effective therapies, including physical therapy and combined approaches, to improve outcomes for ED patients.
Fig. 1: Mechanisms underlying the pathophysiology of erectile dysfunction. (Saikia et al., 2024)
Creative Bioarray's Erectile Dysfunction (ED) Models
Available Animal
- SD Rat
Modeling Method
- Vasculogenic ED Model: Induced by bilateral internal iliac artery ligation.
- Neurogenic ED Model: Induced by cavernous nerve clamping.
- Endocrinologic ED Model: Induced through streptozotocin (STZ) injection.
Endpoints
- Apomorphine (APO)-induced erectile response test: Number of erections
- Intracavernosal pressure (ICP)
- Histology analysis: Masson staining
- Custom endpoints tailored to meet your specific research needs
Example Data
Fig. 2: GLP improved ED in DMED rats. (A) The number and latency of erections after GLP treatment. (B) The representative waves of ICP and MAP as well as the value of ICP/MAP after GLP treatment. (Yao et al., 2022)
Quotation and Ordering
If you are interested in learning more about our Erectile Dysfunction (ED) Models or would like to explore our services further, please do not hesitate to contact us. We welcome your inquiries and are dedicated to supporting your research endeavors with high-quality models and expertise.
References
- Saikia, Q., et al. Erectile dysfunction: basics and its management using plant products. Egyptian Journal of Basic and Applied Sciences, 2024, 11(1): 25-41.
- Yao, X., et al. Ganoderma lucidum polysaccharide ameliorated diabetes mellitus-induced erectile dysfunction in rats by regulating fibrosis and the NOS/ERK/JNK pathway. Translational Andrology and Urology, 2022, 11(7): 982.
For research use only. Not for any other purpose.